No trading signal from this filing. Monitor next quarterly results or material business developments for directional cues.
KMDA drugs
KMDA drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 6 $7.14entry
- T+1 · 3mo ago +1.82%α +1.21% · $7.27
- T+5 · 3mo ago +1.68%α +0.47% · $7.26
- T+20 · 3mo ago +15.83%α +15.23% · $8.27
- T+60 · 18d ago +7.84%α +9.51% · $7.70
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Kamada Ltd. held its Annual General Meeting on August 5, 2026, and shareholders approved all proposals, including re-election of seven directors and two external directors, grant of options to directors, an amendment to the share award plan to increase shares reserved for incentive stock options, and re-appointment of the independent auditor. This is a routine governance filing with no material financial or operational impact.
Key Facts
- Shareholders re-elected seven directors and two external directors (second three-year term).
- Approved grant of options to director nominees and external director nominees.
- Approved amendment to the 2011 Israeli Share Award Plan to increase shares reserved for incentive stock options.
- Re-appointed Kost Forer Gabbay & Kasierer (Ernst & Young) as independent auditor for FY 2026.
Financial Impact
No financial figures disclosed; routine governance approvals only.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-085652 |
| Document: 0001213900-26-085652-index-headers.html | 0001213900-26-085652 |
| Document: 0001213900-26-085652-index.html | 0001213900-26-085652 |
| Document: 0001213900-26-085652.txt | 0001213900-26-085652 |
Track record
25 reports on KMDA
8 of 11 bullish or bearish reports moved the stock their way by T+5. Best: +16.13% at T+20 after the Aug 12, 2026 report. 10 of 11 went positive at some point.
Filters
- Nov 9, 20267d ago 6-K Bullish 6/10 No price data
- Nov 9, 20267d ago Press Release Bullish 6/10 Entry $7.71 to $8.11 Now $8.11 +5.19% ▲ +5.19% +6.88% vs SPY
- Nov 2, 202614d ago 6-K Neutral 2/10 Entry $7.36 to $7.71 Now $8.11 +10.19% ▲ +4.76% +4.68% vs SPY
- Oct 6, 20265w ago 6-K Neutral 4/10 Entry $8.11 to $7.69 Now $8.11 −0.00% ▼ −5.18% −5.04% vs SPY
- Oct 6, 20265w ago Press Release Bullish 6/10 Entry $8.11 to $7.69 Now $8.11 −0.00% ▼ −5.18% −5.04% vs SPY
- Oct 5, 20266w ago 6-K Neutral 2/10 Entry $8.11 to $7.69 Now $8.11 −0.00% ▼ −5.18% −5.04% vs SPY
- Sep 17, 20268w ago 6-K Bullish 6/10 Entry $8.67 to $8.83 Now $8.11 −6.46% ▲ +1.85% +1.24% vs SPY
- Sep 16, 20268w ago EFFECT Neutral 3/10 Entry $8.19 to $8.77 Now $8.11 −0.98% ▲ +7.08% +4.52% vs SPY
- Sep 10, 20269w ago 6-K Neutral 2/10 Entry $7.99 to $8.67 Now $8.11 +1.50% ▲ +8.51% +9.01% vs SPY
- Sep 3, 202610w ago Press Release Neutral 2/10 Entry $8.54 to $8.31 Now $8.11 −5.04% ▼ −2.69% −1.48% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers